AbbVie is considering scrapping the planned £32.4 billion acquisition of Shire drugmaker in what would be the biggest casualty of the US crackdown on so-called tax inversions.
Shire’s stock plummeted the most in 12 years after AbbVie said its board will meet on October 20 to reconsider its recommendation that shareholder approve the deal.
AbbVie expected to lower its tax burden by buying the Dublin-based Shire and moving its legal address to the UK. In...
Subscribe from just €1 for the first month!
All Digital Access + eReader
Unlimited Access for 1 Month
Then €19.99 a month after the offer period.
€149 For the 1st Year
Unlimited Access for 1 Year
90 Day Pass
Get a Business Account for you and your team